Analysts fell to the sidelines weighing in on Gilead Sciences (GILD – Research Report), Globus Medical (GMED – Research Report) and Merck & Company (MRK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Gilead Sciences (GILD)
In a report released today, Joseph Stringer from Needham maintained a Hold rating on Gilead Sciences. The company’s shares closed last Thursday at $65.27, close to its 52-week low of $65.09.
According to TipRanks.com, Stringer is a 2-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $84.65, representing a 25.5% upside. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.
See today’s best-performing stocks on TipRanks >>
Globus Medical (GMED)
In a report released today, Vik Chopra from Wells Fargo maintained a Hold rating on Globus Medical, with a price target of $58.00. The company’s shares closed last Thursday at $50.37.
According to TipRanks.com, Chopra is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $64.89 average price target.
Merck & Company (MRK)
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company, with a price target of $140.00. The company’s shares closed last Thursday at $130.72, close to its 52-week high of $133.10.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $136.61.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Gilead upgraded to Hold from Reduce at HSBC
- Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
- Gilead price target lowered to $75 from $78 at Cantor Fitzgerald
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
